Screener
Allogene Therapeutics ALLO Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $48.92M-21.9% | $40.6M-23.0% | $61.98M-27.5% | $48.11M-21.8% | $62.62M-65.4% | ||
| $293.98M+33.1% | $236.58M-0.4% | $198.52M-8.6% | $214.38M-10.8% | $220.79M-19.4% | ||
| $340M+20.3% | $273.29M-6.3% | $257.75M-15.0% | $260.72M-14.4% | $282.66M-38.2% | ||
| $67.38M-14.6% | $70.02M-15.6% | $72.84M-15.4% | $75.9M-14.7% | $78.86M-14.4% | ||
| $550.09M+16.9% | $395.96M-22.1% | $415.91M-24.2% | $439.77M-25.4% | $470.59M-27.3% | ||
| $5.96M+22.9% | $4.93M-2.5% | $4.27M-20.8% | $3.7M-32.8% | $4.85M-62.5% | ||
| $31.73M+0.2% | $28.33M-5.6% | $32.51M-8.5% | $31.83M-2.3% | $31.68M-15.1% | ||
| $113.92M-9.6% | $117.08M-4.5% | $123.36M-2.5% | $124.44M-0.7% | $126.03M-4.4% | ||
| 800M+100% | 400M0.0% | 400M+188,579% | 400M0.0% | 400M0.0% | ||
| -$2.1B-8.6% | -$2.05B-9.2% | -$2.01B-10.5% | -$1.97B-12.0% | -$1.93B-14.0% | ||
| $436.18M+26.6% | $278.88M-27.6% | $292.54M-30.7% | $315.33M-32.0% | $344.56M-33.1% | ||
| $550.09M+16.9% | $395.96M-22.1% | $415.91M-24.2% | $439.77M-25.4% | $470.59M-27.3% |
FAQ
- What are Allogene Therapeutics's total assets?
- Allogene Therapeutics (ALLO) holds $550.1M in total assets, up 16.9% year over year.
- How much debt does Allogene Therapeutics have?
- Allogene Therapeutics carries $79.0M in total debt against $436.2M of shareholders' equity, a debt-to-equity ratio of 0.18.
- How much cash does Allogene Therapeutics have?
- Allogene Therapeutics holds $48.9M in cash and equivalents.
- Can Allogene Therapeutics cover its short-term obligations?
- Its current ratio is 10.72 — current assets exceed current liabilities.
- Where does Allogene Therapeutics's balance sheet data come from?
- Every line is extracted from Allogene Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
